Journal: Cancer Research
Article Title: Discovery and Evaluation of Biomarkers for Triple-Negative Breast Cancer Subtypes Uncovers Patient Stratification and Targeted Therapeutic Strategies
doi: 10.1158/0008-5472.CAN-24-2758
Figure Lengend Snippet: TAGL as a predictive marker for dasatinib sensitivity. A, Western blot of control and TAGLN -KO cells in Hs578T (top) and BT-549 (bottom) cells. B, Representative immunofluorescence of Hs578T and BT549 control and TAGLN -KO cells, stained with αTAGL (green) and DAPI (blue). Scale bar, 50 μm. C, Cell proliferation in control (black) and TAGLN -KO (purple) cells measured by MTT assays over 72 hours. D, Relative percentage of migrated cells in control and TAGLN -KO cells, assessed by transwell assays. In C and D , values represent the mean ± SEM of at least three experimental replicates, and statistical significance was determined using one-way ANOVA. E, Drug–response curves for cell viability of control and TAGLN -KO cells treated with dasatinib at increasing concentrations. F, Western blot of known dasatinib targets in control and TAGLN -KO cells. G, Data from the DepMap portal showing the correlation between TAGLN and PDGFRB in breast cancer cell lines. H, Western blot of PDGFRβ in TAGLN -KO and cells and clones constitutively expressing PDGFRB . I, Drug–response curves for cell viability of TAGLN -KO and TAGLN -KO/ PBGFRB cells treated with dasatinib at increasing concentrations. In E and I , solid lines represent the mean of three biological replicates performed in technical replicates. The dashed line indicates their IC 50 value. **, P < 0.01; ****, P < 0.0001; ns, not significant.
Article Snippet: For PDGFRB overexpression, lentiviral particles were generated using the PDGFRB Human Tagged Lenti ORF Clone (RC206377L4, OriGene) plasmid and used to transduce target cells.
Techniques: Marker, Western Blot, Control, Immunofluorescence, Staining, Clone Assay, Expressing
R&D Systems is a verified supplier 
R&D Systems manufactures this product 
